Nasdaq Stockholm AB: Oncology Venture A/S receives observation status (105/19)

Yesterday, on March 20, 2019, Oncology Venture A/S published its annual report
for 2018 with information on the company's financial situation. 

The current rules of First North state that a listed company can be given
observation status if any circumstance exists that results in material adverse
uncertainty in respect of the company's financial situation. 

With reference to the above, Nasdaq Stockholm AB has decided that the shares
(OV, ISIN code DK0060732477, order book ID 123713) of Oncology Venture A/S
shall be given observation status. 

For further information about this exchange notice please contact Issuer
Surveillance, telephone + 46 8 405 60 00.